SynthesisArchives of gynecology and obstetrics2022
Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.
Synthesis in Archives of gynecology and obstetrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- Molecular Classification of Endometrial Cancer in the Era of Precision Oncology: Prognostic Significance, Emerging Biomarkers, and Personalized Therapeutic Strategies-A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Integrated Molecular Profiling of Endometrial Cancer: NGS Findings, MSI/MMR Status, Histopathological Features, and TCGA-Inspired Molecular Classification.Biomedicines · 2026Article
- Co-mutations of CTNNB1 and PTEN drive aggressive tumor progression in endometrial cancer.Disease models & mechanisms · 2026Article
- Context-Dependent Alterations of E-Cadherin, β-Catenin, and Vimentin in Endometrial Ciliated Epithelial Change: An Exploratory Immunohistochemical Study.Diagnostics (Basel, Switzerland) · 2026Article
- Molecular Landscape of Advanced Endometrial Cancer: Exploratory Analyses at Modena Cancer Center (MEMO).International journal of molecular sciences · 2026Article
- From integrative diagnostics to personalised management: a framework combining molecular and spatial immune profiling in NSMP endometrial carcinoma.Frontiers in immunology · 2026Review
- Bridging morphology and genomics: p53, mismatch repair proteins, and β-catenin as immunohistochemistry surrogates for risk stratification in endometrial carcinoma.Qatar medical journal · 2026Article
- Fertility-sparing treatment for overweight patients with early-stage endometrial cancer or atypical endometrial hyperplasia under weight loss intervention.Journal of cancer research and clinical oncology · 2025Article
- Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications.Cells · 2025Review
- Novel CTNNB1 gene mutations reveal critical pathogenic mechanisms in pediatric hepatoblastoma.Pediatric surgery international · 2025Article
- Therapeutic Potential of Glucose Oxidase-Loaded Biogenic Mesoporous Silica Nanoparticles in Ovarian Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Does FIGO 2023 meet clinical needs? An analysis of challenges and limitations.Przeglad menopauzalny = Menopause review · 2025Review
- Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes.Journal of clinical medicine · 2025Review
- FBXW7 Directly Ubiquitinates and Degrades CTNNB1 Mediating the Suppression of ENKUR in Endometrial Cancer.International journal of biological sciences · 2025Article
- Identification of key pathways and molecular players potentially involved in endometrial cancer metastasis through integrated bioinformatics analyses.BioImpacts : BI · 2025Article
- β‑catenin expression in endometrioid type endometrial cancer: Expression patterns and impact on disease outcomes.Oncology letters · 2024Article
- Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Review
- Detection of driver mutations and genomic signatures in endometrial cancers using artificial intelligence algorithms.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the last years, mutations in the exon 3 of CTNNB1 have emerged as a possible prognostic factor for recurrence in early stage endometrioid endometrial carcinoma, especially in cases with no specific molecular profile (NSMP).
objectiveTo define the prognostic value of CTNNB1 mutations in early stage endometrioid endometrial carcinoma, through a systematic review and meta-analysis.
methodsElectronic databases were searched from their inception to November 2020 for all studies assessing the prognostic value of CTNNB1 mutation in early stage (FIGO I-II) endometrioid endometrial carcinoma. Odds ratio (OR) for tumor recurrence and hazard ratio (HR) for disease-free survival (DFS) were calculated with a significant p value < 0.05.
resultsSeven studies with 1031 patients were included. Four studies were suitable for meta-analysis of OR and showed significant association between CTNNB1 mutation and the absolute number of recurrence (OR = 3.000; p = 0.019); the association became stronger after excluding patients with known molecular status other than NSMP (HR = 5.953; p = 0.012). Three studies were suitable for meta-analysis of HR and showed no significant association between CTNNB1 mutation and decreased DFS (HR = 1.847; p = 0.303); the association became significant after excluding patients with known molecular status other than NSMP (HR = 2.831; p = 0.026).
conclusionCTNNB1 mutation is significantly associated with recurrence in early stage endometrioid endometrial carcinomas, especially in the NSMP, appearing potentially useful in directing adjuvant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.